We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Narsoplimab

News List

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA FirstWordPharma
January 20, 2022
Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency's Complete Response Letter (CRL) for narsoplimab...
Omeros reports positive results for Narsoplimab in treatment of Covid-19-associated ARDS pharmaceutical-business-review
August 13, 2020
Omeros Corporation reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) ...
Omeros, Lonza Enter Commercial Manufacturing Agreement contractpharma
August 01, 2019
Builds on existing clinical supply deal for narsoplimab.